U.S. markets close in 2 hours 28 minutes

Apexigen, Inc. (APGN)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
7.44-0.18 (-2.36%)
As of 01:14PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Inside Bar (Bullish)

Inside Bar (Bullish)

Previous Close7.62
Bid7.16 x 1000
Ask7.45 x 900
Day's Range6.93 - 7.71
52 Week Range5.11 - 31.35
Avg. Volume111,879
Market Cap159.551M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for APGN

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Apexigen, Inc.
    Analyst Report: Merck & Co IncMerck & Co. is a worldwide pharmaceutical company. Its major drugs include treatments in oncology and diabetes. The company also has a leading vaccine business and an animal health division. MRK shares are included in the S&P 500.
    Fair Value
    Economic Moat
    6 days agoArgus Research
View more
  • Simply Wall St.

    Is Apexigen (NASDAQ:APGN) In A Good Position To Deliver On Growth Plans?

    Just because a business does not make any money, does not mean that the stock will go down. For example, although...

  • GlobeNewswire

    Apexigen to Participate in the 2022 Wedbush PacGrow Healthcare Conference

    SAN CARLOS, Calif., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Apexigen, Inc. (NASDAQ: APGN) a clinical-stage company focused on developing innovative antibody-based therapeutics for the treatment of cancer with a focus on immuno-oncology, today announced that the Company’s Management will participate virtually in the Wedbush PacGrow Healthcare Conference on Tuesday, August 9, 2022. 2022 Wedbush PacGrow Healthcare ConferenceFormat: Panel discussion and one-on-one investor meetingsTopic: For Your IOnly -